Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FSD201 in Hospitalized COVID-19 Patients
NCT04619706Phase 2Terminated
- Sponsor
- Quantum BioPharma Ltd.
- Start
- Dec 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of palmitoylethanolamide in coronavirus disease 2019 (COVID-19), sponsored by Quantum BioPharma Ltd. Primary endpoint: Percentage of Participants With Disease Progression at Day 28. Started Dec 2020; status: terminated.
02
Drugs
palmitoylethanolamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04619706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619706.